Skip to main content
SpringerLink
Log in

Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus

  • Original Research Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Background: Pioglitazone as monotherapy and in combination with sulfonylurea, metformin, or insulin has consistently demonstrated improved glycaemic and lipid parameters in patients with type 2 diabetes mellitus.

Objective: We performed a subanalysis to examine the effect of pioglitazone on glycaemia and lipids in patients <65 and ≥65 years of age in two double-blind, placebo-controlled monotherapy studies and in three separate multi-centre trials.

Method: In Study 1, 197 patients were randomised to receive pioglitazone 30 mg/day or placebo for 16 weeks. Study 2 was a forced dose-titration trial in patients randomised to receive pioglitazone 7.5/15/30 mg/day, pioglitazone 15/30/45 mg/day, or placebo daily for 26 weeks. Each of the lower dosages was given for at least 4 weeks and the highest dosage for 16 weeks. The three combination studies evaluated efficacy of pioglitazone 30 or 45 mg/day over a 24-week period in combination with sulfonylureas, metformin, or insulin.

Results: In both placebo-controlled monotherapy studies, at 16 weeks, and at maximum pioglitazone dosage, 0.53–0.55% and 0.57–1.27% mean reductions from baseline in glycosylated haemoglobin (HbA1c) were seen in patients aged <65 (n = 225) and ≥65 (n = 45) years, respectively. There were statistically significant differences between the placebo and pioglitazone groups in each age cohort. Similar effects were observed in fasting plasma glucose (FPG) levels, with 2.03–2.59 mmol/L and 3.20–4.44 mmol/L mean reductions from baseline, respectively, which were significantly different from the changes in the placebo group, but there was no difference between pioglitazone groups. At treatment endpoint in combination trials, pioglitazone added to sulfonylurea produced a mean decrease in HbA1c of 0.78–1.61%, and 1.64–1.96% in patients aged <65 (n = 557) and ≥65 (n = 115) years, respectively. Pioglitazone added to metformin produced a mean decrease in HbA1c of 0.78–1.03% and 0.78–0.98% in patients aged <65 (n = 686) and ≥65 (n = 112) years, respectively. Pioglitazone added to insulin produced a mean decrease in HbA1c of 1.13–1.37% and 1.39–1.66% in patients aged <65 (n = 500) and ≥65 (n = 156) years, respectively. In patients aged ≥65 years, hypoglycaemia was observed in 1 of 14 patients and in 0 of 13 patients in the two monotherapy studies. In the combination studies, the incidence of hypoglycaemia among patients aged ≥65 years was as follows: 26.7–28.8% combined with sulfonylurea; 0–4.4% combined with metformin; and 53.4–56.4% combined with insulin.

Conclusion: Pioglitazone monotherapy, or added to a sulfonylurea, metformin, or insulin demonstrated no significant differences in effectiveness while exhibiting similar adverse events in patients aged ≥65 years compared with patients aged <65 years. Well-controlled randomised clinical trials are recommended to confirm the impact of pioglitazone therapy on the glycaemic and lipid control in elderly patients with type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Table IV
Table V
Table VI
Table VII

Similar content being viewed by others

References

  1. Seltzer HA. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin North Am 1989; 18(1): 163–82

    PubMed  CAS  Google Scholar 

  2. Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997; 50(6): 735–41

    Article  PubMed  Google Scholar 

  3. Hepburn DA, Patrick AW, Eadington DW, et al. Unawareness of hypoglycemia in insulin-treated diabetic patients: prevalence and relationship to autonomic neuropathy. Diabet Med 1990; 7: 711–7

    Article  PubMed  CAS  Google Scholar 

  4. Kobayashi KA, Bauer A, Horn JR, et al. Glipizide pharmacokinetics in young and elderly volunteers. Clin Pharm 1998; 7: 224–8

    Google Scholar 

  5. Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157: 1681–6

    Article  PubMed  CAS  Google Scholar 

  6. UK prospective study of therapies of maturity onset diabetes (I): effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia 1983; 24: 404–11

    Google Scholar 

  7. Hall GC, Luscombe DK, Walker SR. Post-marketing surveillance using a computerized general data base. Pharm Med 1988; 2: 345–51

    Google Scholar 

  8. Peters AL, Davidson MB. Use of sulfonylurea agents in older diabetic patients. Clin Geriatr Med 1990; 6(4): 903–21

    PubMed  CAS  Google Scholar 

  9. Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technol Ther 2003; 5(1): 19–26

    Article  PubMed  CAS  Google Scholar 

  10. Chehade JM, Mooradian AD. A rational approach to drug therapy to type 2 diabetes mellitus. Drugs 2000 Jul; 60(1): 95–113

    Article  PubMed  CAS  Google Scholar 

  11. White Jr JR, Campbell RK. The management of type 2 diabetes in the elderly patient. J Geriatr Drug Ther 1999; 12(2): 21–45

    Google Scholar 

  12. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 1989; 12: 203–8

    Article  PubMed  CAS  Google Scholar 

  13. Fink RI, Revers RR, Kolterman OG, et al. The metabolic clearance of insulin and the feedback inhibition of insulin secretion are altered with aging. Diabetes 1985; 34: 275–80

    Article  PubMed  CAS  Google Scholar 

  14. Oiknine R, Mooradian AD. Drug therapy of diabetes in the elderly. Biomed Pharmacother 2003; 57(5–6): 231–9

    Article  PubMed  CAS  Google Scholar 

  15. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231–41

    Article  PubMed  CAS  Google Scholar 

  16. Cryer PE, Fisher JN, Shamoon H. Hypoglycemia. Diabetes Care 1994; 17: 734–55

    PubMed  CAS  Google Scholar 

  17. Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002; 347(12): 878–934

    Article  PubMed  Google Scholar 

  18. Kapoor WN. Syncope. N Engl J Med 2000; 343(25): 1856–62

    Article  PubMed  CAS  Google Scholar 

  19. Gregg EW, Yaffe K, Cauley JA, et al. Is diabetes associated with cognitive impairment and cognitive decline among older women. JAMA 2000; 160: 174–80

    Article  CAS  Google Scholar 

  20. Defronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131(4): 281–303

    PubMed  CAS  Google Scholar 

  21. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patient with type 2 diabetes: a 6-month randomized, placebo-controlled dose-response study. Diabetes Care 2000; 23(11): 1605–11

    Article  PubMed  CAS  Google Scholar 

  22. Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413–23

    Article  PubMed  CAS  Google Scholar 

  23. Einhorn D, Rendell M, Rosenzweig J. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized controlled trial. Clin Ther 2000; 22: 1395–409

    Article  PubMed  CAS  Google Scholar 

  24. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med 2002; 347(17): 1342–9

    Article  PubMed  Google Scholar 

  25. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001; 111(1): 10–7

    Article  PubMed  CAS  Google Scholar 

  26. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001; 7(3): 162–9

    PubMed  CAS  Google Scholar 

  27. ACTOS® prescribing information. Lincolnshire (IL): Takeda Pharmaceuticals America Inc., 2002 Jul

  28. Data on file, Takeda Pharmaceuticals

  29. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039–57

    Google Scholar 

  30. Milliken GA, Johnson DE. Analysis of messy data: analysis of covariance. Arlington (VA): The Institute of Professional Education, 1989

    Google Scholar 

  31. Morrison, DF. Multivariate statistical methods. New York: Mc-Graw Hill, 1976

    Google Scholar 

  32. Bachorik PS. National cholesterol education program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. Clin Chem 1995; 41(10): 1414–20

    PubMed  CAS  Google Scholar 

  33. Boyle PJ, King AB, Olansky L. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378–96

    Article  PubMed  CAS  Google Scholar 

  34. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695–702

    Article  PubMed  CAS  Google Scholar 

  35. Khan MA, St Peter JV, Xue JL. A prospective randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25: 708–11

    Article  PubMed  CAS  Google Scholar 

  36. Mooradian AD, Chehade J, Thurman JE. The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus. Treat Endocrinol 2002; 1(1): 13–20

    Article  PubMed  Google Scholar 

  37. Goldstein B. Differentiating members of the thiazolidinedione class: a focus on efficacy. Diabetes Metab Res Rev 2002; 18: S16–22

    Article  PubMed  CAS  Google Scholar 

  38. Reasner CA. Where thiazolidinediones will fit. Diabetes Metab Res Rev 2002; 18: S30–5

    Article  PubMed  CAS  Google Scholar 

  39. Raskin P, Rendell M, Riddle M. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226–32

    Article  PubMed  CAS  Google Scholar 

  40. Avandia® prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2003 Mar

  41. Buysschaert M, Bobbioni E, Starkiet M, et al. Troglitazone in combination with sulphonylurea improves glycemic control in type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Diabet Med 1999; 16: 147–53

    Article  PubMed  CAS  Google Scholar 

  42. Yu J, Kruszynska Y, Mulford M. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes 1999; 48: 2414–21

    Article  PubMed  CAS  Google Scholar 

  43. Schwartz S, Raskin P, Fonseca V. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. N Engl J Med 1998; 338: 861–6

    Article  PubMed  CAS  Google Scholar 

  44. Lebovitz H. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002; 18: S23–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

All authors are employees of Takeda Pharmaceuticals North America, Inc.

Author information

Authors and Affiliations

  1. Medical and Scientific Affairs Department, Takeda Pharmaceuticals North America Inc., Lincolnshire, 475 Half Day Road, Illinois, 60069, USA

    Rukmini Rajagopalan, Alfonso Perez, Zhan Ye, Mehmood Khan & Frederick T. Murray

Authors
  1. Rukmini Rajagopalan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alfonso Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhan Ye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mehmood Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Frederick T. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rukmini Rajagopalan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rajagopalan, R., Perez, A., Ye, Z. et al. Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus. Drugs Aging 21, 259–271 (2004). https://doi.org/10.2165/00002512-200421040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200421040-00004

Keywords

Search

Navigation